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Human 1-acid glycoprotein (hAGP) in serum functions as a
carrier of basic drugs. Inmost individuals, hAGP exists as amix-
ture of two genetic variants, the F1*S andA variants, which bind
drugswith different selectivities.Weprepared amutant of theA
variant, C149R, and showed that its drug-binding properties
were indistinguishable from those of thewild type. In this study,
we determined the crystal structures of thismutant hAGP alone
and complexed with disopyramide (DSP), amitriptyline (AMT),
and the nonspecific drug chlorpromazine (CPZ). The crystal
structures revealed that the drug-binding pocket on the A vari-
ant is located within an eight-stranded -barrel, similar to that
found in the F1*S variant and other lipocalin family proteins.
However, the binding region of the A variant is narrower than
that of the F1*S variant. In the crystal structures of complexes
withDSP andAMT, the two aromatic rings of each drug interact
with Phe-49 and Phe-112 at the bottom of the binding pocket.
Although the structure of CPZ is similar to those of DSP and
AMT, its fused aromatic ring system, which is extended in
length by the addition of a chlorine atom, appears to dictate an
alternative mode of binding, which explains its nonselective
binding to the F1*S and A variant hAGPs. Modeling experi-
ments based on the co-crystal structures suggest that, in com-
plexes of DSP, AMT, or CPZ with the F1*S variant, Phe-114
sterically hinders interactions withDSP andAMT, but not CPZ.
Human 1-acid glycoprotein (hAGP),2 a serum glycoprotein
composed of 183 amino acid residues, contains five N-linked
glycans that account for about half of the total 40-kDa mass of
the protein (1, 2). hAGP is an acute-phase protein; its blood
concentration is therefore significantly increased in inflamma-
tory states (e.g. tumor growth) (3). The protein is a member of
the lipocalin family of proteins and is known to be a carrier of
hydrophobic ligands (4). hAGP also binds to a variety of drugs
that are predominantly apolar but with some basic characteris-
tics (4) and thereby regulates their tissue distribution. For
example, the anticancer drug UCN-01 has a long half-life and a
small distribution volume in patients because of its high bind-
ing affinity for hAGP (5).Moreover, the serumconcentration of
imatinib, a tyrosine kinase inhibitor used in the treatment of
leukemia, was reported to be positively correlated with that
of hAGP (6). Treatment regimes in cancer patients can be com-
plicated by the fact that hAGP levels are increased as the result
of their inflammatory state, thereby increasing the impact of
the protein on the pharmacokinetics of drugs that bind to it (5,
6). Consistent with this, transgenic mice expressing excess rat
AGP exhibited a lower clearance and a smaller distribution vol-
ume (compared with control mice) for the HIV protease inhib-
itor saquinavir, which binds to the protein (7).
In most individuals, hAGP exits as a mixture of F1*S and A
variants. The molar ratio of the F1*S and A variants in blood
typically ranges from 3:1 to 2:1 (8, 9). However, Ve´key and co-
workers (10) reported that, in plasma of some cancer patients,
AGP levels were increased by 4-fold and that the molar ratio of
the F1*S and A variants was in the vicinity of 8:1. Therefore, the
pharmacokinetics and pharmacodynamics of drugs that bind to
hAGP are affected during inflammation not only as the result of
increased hAGP concentrations but also by the change in the
ratio of the hAGP variants.
Herve´ et al. (11) reported that F1*S and A variants showed
different drug-binding selectivities. For example, the F1*S var-
iant of hAGP had a higher selectivity for dipyridamole (17-fold)
than the A variant; conversely, compared with F1*S, the A
variant bound propafenone, amitriptyline, desipramine, imip-
ramine, and nortriptyline with 15-, 46-, 12-, 12-, and 27-fold
higher selectivities, respectively. These A variant-specific drugs
have similar structures, probably reflecting unique structural
features of the drug-binding site on this variant of hAGP. How-
ever, the mechanism underlying the drug selectivity of the A
variant has yet to be established.
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Attempts tomap the amino acids involved in drug binding of
hAGP have been made using a range of different experimental
approaches, including fluorescent probe displacement (12),
chemical modification (13, 14), photoaffinity labeling (15, 16),
and other spectroscopic methods (17). However, most of these
investigations used mixtures of hAGP variants, resulting in
some contradictory results. A significant step toward clarifying
the structural basis of the drug-binding specificity of hAGPwas
made recently when Skerra and co-workers (18) reported the
first high-resolution x-ray structural analysis of hAGP. They
determined the crystal structure of the F1*S variant, produced
by overexpression in Escherichia coli, and showed that F1*S
hAGP has a drug-binding pocket located in the center of an
eight-stranded -barrel structure, which is characteristic of the
lipocalin family of proteins. The binding pocket consists of
three distinct “lobes,” I–III. Lobe I is the largest and deepest
cavity in the protein and appears to serve as the main hydro-
phobic drug-binding chamber. Lobes II and III project from the
central lobe I and are smaller and negatively charged. Although
Skerra and co-workers were unable to obtain co-crystals of
hAGP-drug complexes, they used computational docking pro-
tocols to model the likely interactions of diazepam and proges-
terone for their binding to F1*S hAGP. Their model predicted
that diazepam binds to lobe I, whereas progesterone binds to
lobe II, and they proposed that the unique geometry of the
binding pocket of the F1*S variant explains the diverse ligand
spectrum of F1*S. This result is in good agreement with our
findings indicating that AGP has a wide binding site consisting
of three different subsites (19).
Despite these advances, obtaining more direct structural
information on the drug-binding properties of hAGP continues
to be an important issue. To this end,we previously constructed
expression systems inE. coli that allowboth F1*S andAvariants
to be produced (20).We found that the introduction of aC149R
mutation into the A variant of hAGP, in which a surface-ex-
posed Cys residue was replaced by an Arg residue (as found in
F1*S), yields a much more homogeneous protein sample with-
out any detectable alterations in the drug-binding specificity of
the protein. We report here on the crystal structure of this
C149R mutant of the A variant (hereafter referred to as the A
variant). In addition, we also determined the crystal structures
of complexes of this A variant hAGP with disopyramide (DSP)
and amitriptyline (AMT), which bind to the A variant with a
high degree of selectivity, and chlorpromazine (CPZ), which
binds with less selectivity. Comparison of our results with the
structure of the F1*S variant provides important new insights
into the mechanism of the drug-binding selectivity of hAGP
variants.
EXPERIMENTAL PROCEDURES
Materials—The pT-Trx vector was a gift from Dr. Shunsuke
Ishii (Laboratory ofMolecular Genetics, RIKENTsukuba Insti-
tute, Tsukuba, Japan). The pET Expression System 3 and Ori-
gami B(DE3) were purchased from Novagen. Restriction
enzymes, the DNA ligation kit, and the DNA polymerase Pre-
mixTaq (ExTaq version)were obtained fromTakara Biotech-
nology (Kyoto, Japan). The DNA sequencing kit was obtained
from PerkinElmer Life Sciences. Isopropyl -D-thiogalactopy-
ranoside was purchased from Promega (Madison, WI). AMT,
DSP, and CPZ were purchased from Sigma. HiTrap chelating
HP and Q-XL columns and Sephadex G-100 were purchased
from Amersham Biosciences. All other chemicals and solvents
were of analytical grade.
Construction of Recombinant F1*S and A Variant Expression
Vectors—For expression of the recombinant F1*S and A vari-
ants, the pET-3c vector, which is frequently used as an
expression system in E. coli, was utilized (see Fig. 1). The
cDNA of the F1*S variant was a gift from Kyowa Hakko Co.,
Ltd. (Tokyo, Japan). The cDNA of the A variant was prepared
according to our previous method (19). A DNA fragment
encoding the F1*S or A variant containing a His6 tag was
amplified by PCR using each template and the following
oligonucleotide primers: 5-GGTCATATGCAGATCC-
CATTGTGTGCCAACCTAGTACCGG-3 (5-NdeI) and
5-GGTGGATCCTCACTAGTGGTGGTGGTGGTGGTG-
GGATTCCCCCTCCTCCTGTTTCC-3 (3-BamHI) and
inserted into the restriction enzyme sites NdeI and BamHI in
a multicloning site on this vector.
Introduction of Mutations into the A Variant Coding Region—
Site-directed mutagenesis was performed to replace cysteine
with arginine at position 149 in A variant hAGP using the
QuikChange XL site-directed mutagenesis Kit (Qiagen). Com-
plementary mutagenic primers were synthesized according to
the forward sequence 5-CTCGACTGCTTGCGCATTCCCA-
GGTCA-3 (the underlined letter indicates a mismatch). The
mutation in themutated genewas confirmed byDNA sequenc-
ing of the entire A variant coding region using the dideoxy
chain termination method with a PerkinElmer ABI Prism 310
genetic analyzer.
Expression of Recombinant F1*S and A Variants and C149R
in E. coli (Origami B(DE3) Strains)—pET-3c vectors containing
the inserted cDNA for the A variant (pET-3c/A) were trans-
formed in the Origami B(DE3) strain that had been pretrans-
formed with pT-Trx. After culturing this transformant in LB
medium containing 2% glucose, 50 g/ml ampicillin, and 25
g/ml chloramphenicol at 30 °C for 18 h, a 20-ml aliquot of
the medium was cultured for 18 h in 2 yeast extract/tryptone
medium (1 liter) containing 2% glucose and 50 g/ml ampicil-
lin. After reaching an appropriate A value at 600 nm (A600 
0.5), recombinant AGP expression was induced for 3 h by the
addition of 0.1 mM isopropyl -D-thiogalactopyranoside. After
centrifugation (3000  g, 15 min, 4 °C), the pellet was sus-
pended in 20 mM Tris-HCl (pH 8.0), 50 mMNaCl, 20 mM imid-
azole, and 0.1% CHAPS and sonicated. After centrifugation
(15,000  g, 20 min, 4 °C), the soluble and insoluble proteins
were recovered in the supernatant and pellet, respectively. The
supernatant was loaded on aHiTrap chelating HP column. The
target protein was eluted with 20mMTris-HCl (pH 8.0), 50mM
NaCl, 100mM imidazole, and 0.1%CHAPS.The eluatewas then
loaded on a HiTrapQ-XL column. The protein was eluted with
20 mM Tris-HCl (pH 8.0) and 0.1% CHAPS using a linear gra-
dient of 0–1.0 M NaCl. Finally, the eluate was loaded onto a
Sephadex G-100 column and eluted with 20 mM Tris-HCl (pH
7.4) containing 50 mM NaCl.
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Crystallization of C149R and Complexes with DSP, AMT,
andCPZ—In aprevious study (20), we reported that the recom-
binant wild-type A variant expressed from E. coli underwent
oligomerization due to the formation of intermolecular disul-
fide bonds but that a mutation of Cys-149 to Arg yielded a
monomeric protein that could be purified to homogeneity and
had a drug-binding capacity comparable with that of the A var-
iant isolated from serum. Therefore, crystallization trials of the
recombinant A variant were carried out using the mutant
(C149R) (see Table 1). Crystallization was performed by hang-
ing-drop vapor diffusion at 20 °C. Crystals of the A variant were
grown from a droplet (3 l) consisting of equal volumes of the
protein solution (18mg/ml) and the reservoir solution contain-
ing 0.2 M ammonium acetate, 0.1 M sodium acetate (pH 4.6),
and 26% (w/v) polyethylene glycol 4000. For co-crystallization
experiments with drugs, the protein solutions were incubated
with 5 mM AMT, 5 mMDSP, and 5 mM CPZ at 20 °C for12 h,
respectively. All complex crystals (A variant-AMT complex, A
variant-DSP, and A variant-CPZ complex) were obtained
under conditions similar to those for the drug-free A variant.
(The concentration of polyethylene glycol 4000 was 21–25%.)
The crystals were transferred into a cryoprotectant solution
composed of reservoir solution containing 10% glycerol and
flash-frozen in a stream of nitrogen at 100 K. Diffraction data
were collected on beamline BL44XU at SPring-8 (Harima,
Japan) and on beamlines NW12A, BL-5A, and BL-17A at the
Photon Factory (Tsukuba, Japan). The data sets for A variant, A
variant-AMT complex, and A variant-CPZ complex were
indexed, integrated, and scaled with HKL2000 (21). The data
set for A variant-DSP complex was indexed, integrated, and
scaled with iMOSFLM (22) and SCALA (23) in the CCP4 pro-
gram suite. Crystals of the A variant, A variant-AMT complex,
and A variant-DSP complex belong to space group C2 with the
unit cell dimensions listed in Table 1. The crystal of A variant-
CPZ complex belongs to space group P212121.
The structure of the A variant was determined by molecular
replacement withMOLREP (24) using the structure of the F1*S
variant as a search model (Protein Data Bank code 3BX6) (18).
The model was refined with CNS (25) and rebuilt with COOT
(26). The structures of A variant-AMT complex and A variant-
DSP complex were refined with the coordinates of the A vari-
ant, respectively. The structure of A variant-CPZ complex was
determined bymolecular replacement withMOLREP using the
structure of A variant as a search model. At the final stages, the
refinement of each structure was carried out with REFMAC
using the TLS parameters (27). The stereochemical qualities of
all structures were checked by PROCHECK (28). Data collec-
tion and refinement statistics are given in Table 1. Superposi-
tions of the hAGP structures were carried out with LSQKAB
(29). All figures of protein structures were generated with
PyMOL (30) and CCP4mg (31). The electrostatic surface
potential was calculated and drawn with CCP4mg.
RESULTS
Tertiary Structure of the A Variant—The crystal structure of
drug-free A variant hAGPwas determined at a resolution of 2.1
Å. As shown in Fig. 1, the A variant is composed of four -
helices, 1–4, corresponding to Asn-15–Ile-21, Glu-35–Gln-42,
Lys-135–Cys-147, and Glu-166–Gln-171, respectively, and
eight -strands, A–H, corresponding to Gly-23–Phe-32, Ile-
44–Asn-54, Thr-59–Arg-68, Gln-71–Gln-82, Thr-87–Glu-92,
Arg-95–Leu-102, Thr-109–Ser-114, and Gly-123–Ala-128,
respectively. These eight -strands form a -barrel, which is a
common structural feature in other proteins of the lipocalin
family. The entrance to the ligand-binding pocket is located at
the open end of the -barrel. The five glycans of AGP are
attached to Asn-15, Asn-38, Asn-54, Asn-75, and Asn-85,
respectively; among these residues, only Asn-75 is in close
proximity to the entrance of the binding pocket (Fig. 1b). It was
observed that a PEG molecule derived from the reservoir solu-
tion is bound in the binding pocket (supplemental Fig. S1).
Modes of Binding of DSP, AMT, and CPZ to the A Variant—
We successfully obtained the crystal structures of complexes of
A variant hAGP with DSP, AMT, and CPZ at resolutions of
2.20, 2.15, and 2.20 Å, respectively. The complexes with DSP
andAMTcrystallized in the same space group (C2) as drug-free
hAGP andwith essentially the same unit cell dimensions (Table
1), and each crystal contains two protein-drug complexes in the
asymmetric unit (molecules A and B). In both cases, the A and
B structures were very similar to one another, so, for the sake
FIGURE 1. a, crystal structure of the A variant (C149R) of hAGP at a resolution of 2.10 Å shown as a ribbon diagram. Secondary structures are colored lime green
(-strands) and light magenta (-helices). Cys residues are depicted as orange sticks and balls. Asn residues of five N-linked glycosylation sites are depicted as
yellow sticks and balls. Nitrogen and oxygen are colored blue and red, respectively. b, top view into the -barrel with surface representation. Asn residues
corresponding to glycosylation sites are colored yellow.
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of simplicity, the discussion below refers to molecule A. The
hAGP-CPZ complex crystallized in a different space group
(Table 1) with only one complex in the asymmetric unit.
We were able to clearly observe the electron density for DSP
in the binding pocket of A variant hAGP (Fig. 2a). Although
there are both S- andR-forms ofDSP, it is not easy to determine
from the electron density whether the S- or R-form is bound
because of the similarity in electron densities between the pyr-
idinyl and phenyl rings. Because hAGP is known to bind pref-
erentially to the S-form of DSP (32), the structure of the hAGP-
DSP complex was refined using the S-form of DSP (Fig. 2b).
DSP makes multiple contacts with residues lining the binding
pocket. The two aromatic rings of DSP are in direct contact
with Phe-49 and Phe-112, resulting in CH- interactions (edge
to face); in addition, van der Waals contacts with Glu-64 and
Arg-90 are observed. In the S-formofDSP, the nitrogen atomof
the pyridinyl ring can be located near the guanidium group of
Arg-90, whichmight contribute to preference for the S-form by
the A variant. The amide group of DSP forms a hydrogen bond
with the hydroxyl group of Tyr-127. Further specific hydrogen
bondswith the amide group of the drug inmolecule A aremade
via a water molecule (Fig. 2c), which is held in position by
hydrogen bonding with Ser-114 and Ser-125. Finally, the alkyl
chain of DSP makes van der Waals interactions with Tyr-27,
Tyr-37, Val-41, and Ile-44 (Fig. 2b).
In the case of AMT (Fig. 2d), again the electron density
clearly indicated the binding of a single drug molecule. Similar
to DSP, the aromatic rings of AMT are involved in CH- inter-
actions (edge to face) with Phe-49 and Phe-112 and van der
Waals interactions with Leu-62 and Arg-90. The tip of the alkyl
chain of AMT makes van der Waals contacts with Tyr-37 and
Val-41. It is noteworthy that the side chain of Tyr-37 is rotated
compared with its position in the complex with DSP. (The dif-
ference in the side chain torsion angle (2) is39°.) This differ-
ence in the rotation of the Tyr-37 side chain may contribute to
the ability of this protein to bind drugs with different lengths of
alkyl chains.
Interestingly, CPZ shows a different interaction mode in the
binding pocket compared with DSP and AMT (Fig. 2e). In this
case, the fused aromatic ring system of CPZ interacts with Phe-
112 by - stacking interactions; in addition, it makes CH-
interactions with Phe-49 and Ala-99. Further van der Waals
contacts are made with Phe-51, Val-88, and Arg-90. The chlo-
rine atom attached to one end of the aromatic ring system in
CPZ is accommodated at the end of the binding pocket formed
by the side chains of Thr-47, Phe-49, Glu-64, and Tyr-127.
Comparison with the F1*S Variant of hAGP—In Fig. 3a, the
21 amino acid residues of the A variant that are different from
the F1*S variant are shown in red. These are distributed
throughout the molecule, but many are found lining the inte-
rior of the pocket (there is a near-continuous stretch of substi-
tutions in strand G and along the GH loop) and near its
entrance (Fig. 3, a and b). Superposition of the tertiary struc-
tures of the A and F1*S variants of hAGP reveals that their
overall folds are similar (root mean square deviation of 1.37 Å
for 168 C atoms) (Fig. 3c). However, there are some notable
differences in both structures: the angle of -helix 2 relative to
strands A and B is substantially altered, being rotated by 16°
compared with its position in the F1*S variant (Fig. 3c). This
rotation appears to be due primarily to the presence of the bulk-
ier side chain of Met-156 in the A variant (compared with Val-
156 in the F1*S variant), which changes the nature of the inter-
actions with Asn-38, Val-41, and Gln-42, moving -helix 2
toward the pocket (Fig. 3d). In the loop between strands G and
TABLE 1
Data collection and refinement statistics
Values in parentheses correspond to the highest resolution shell. PF, Photon Factory; r.m.s.d., root mean square deviation.
Apo form (PEG complex) AMT complex DSP complex CPZ complex
Data collection
Beamline SPring-8 BL44XU PF BL-5A PF BL-17A PF BL-5A
Space group C2 C2 C2 P212121
Unit cell constants a 67.1, b 44.9, c 120.8 Å;
 91.9°
a 66.7, b 45.9, c 120.7 Å;
 92.1°
a 66.7, b 45.5, c 120.6 Å;
 91.7°
a 42.1, b 63.1,
c 65.0 Å
Resolution range (Å) 50.0–2.10 (2.18–2.10) 50.0–2.15 (2.23–2.15) 40.19–2.20 (2.32–2.20) 50.0–2.20 (2.28–2.20)
No. of observed reflections 152,696 133,660 139,452 47,798
No. of unique reflections 21,258 20,082 18,846 9216
Completeness (%) 99.9 (99.3) 98.8 (93.8) 99.6 (100.0) 99.2 (95.2)
Rmerge (%)a 4.4 (32.6) 5.9 (17.7) 5.8 (10.5) 7.9 (16.1)
I/I 56.8 (6.7) 52.4 (8.1) 26.2 (15.2) 27.6 (8.7)
Refinement statistics
Resolution range (Å) 31.99–2.10 36.31–2.15 40.19–2.20 30.83–2.20
No. of reflections used 20,189 18,955 17,931 8671
Completeness (%) 99.9 98.9 99.5 99.3
Rcryst/Rfree (%)b 20.0/23.2 21.9/26.7 22.8/26.3 20.2/26.8
No. of atoms
Protein 2882 2871 2945 1503
Water 83 96 74 138
Ligand 26 46 50 25
Ramachandran plot (%)
Most favored 94.0 92.0 93.1 95.7
Additionally allowed 6.0 8.0 6.9 4.3
Generously allowed 0 0 0 0
Disallowed 0 0 0 0
r.m.s.d.
Bonds (Å) 0.012 0.013 0.012 0.008
Angles 1.3° 1.4° 1.3° 1.1°
aRmerge 100 Ihkl	 Ihkl/Ihkl, where Ihkl is the mean value of Ihkl.
bRcryst 100 Fo 	 Fc/Fo. Rfree was calculated from the test set (5% of the total data).
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H(positions 112–117), Tyr-115 in theA variant is also observed
to project inside the binding pocket (Fig. 3e), whereas Asp-115
in the F1*S variant enters into hydrogen bond formation with
the side chain of His-100 at the side of the pocket. These col-
lective differences account for the formation of the van der
Waals interactions among Asn-34, Tyr-37, Tyr-115, and Asn-
121 and a hydrogen bond between Tyr-37 and His-97 in the
structure of theA variant (Fig. 3e), which reduce thewidth of its
binding pocket. Indeed, these changes effectively eliminate the
lobe III subcompartment of the drug-binding pockets that were
identified in F1*S hAGP by Scho¨nfeld and co-workers (18) (Fig.
4, a and b).
DISCUSSION
Tertiary Structure of the A Variant—The structural and
functional properties of hAGP have been a subject of consider-
able interest since the protein was first purified from serum in
the 1950s. In these prior investigations, hAGP was found to
have a high content of glycan structure, which makes up about
half of the total mass of this glycoprotein (1, 2). These glycans,
which are thought to contribute to the aqueous solubility of
hAGP, undoubtedly add to its structural heterogeneity and
have made it difficult to obtain the single crystals needed for
structure determination by x-ray crystallography. However,
Skerra and co-workers (18) recently succeeded in determining
the crystal structure of the recombinant F1*S variant of hAGP
expressed from E. coli in the form of an unglycosylated protein.
They found that the F1*S variant has a typical lipocalin fold
consisting of an eight-stranded -barrel, which forms a deep,
wide drug-binding pocket. In this study, we employed a similar
approach to determine the crystal structure of an unglycosy-
lated form of the A variant of hAGP. Our results confirm that
this protein has the sameoverall folding as the F1*S variant. The
carbohydrate groups on hAGP are thought to have little effect
on drug-binding properties and secondary structure (33, 34).
Our previous findings also demonstrated that the drug-binding
capacity of a mutant, C149R, was equivalent to that of the A
formpurified from serum (35). Although it should be noted that
Asn-75, which is glycosylated in vivo in both variants, was
FIGURE2. InteractionsofDSP,AMT,andCPZwith theAvariant.a, 2Fo	 FcelectrondensitymapsofDSP,AMT, andCPZ in the complex structures, contoured
at 1.2. b, structure of the binding pocket in the A variant-DSP complex. c, structure of the binding pocket in the A variant-DSP complex. A water molecule is
depicted as a blue sphere, and hydrogen bonds are indicated as black dotted lines. d, structure of the binding pocket in the A variant-AMT complex. e, structure
of the binding pocket in the A variant-CPZ complex. DSP, AMT, and CPZ molecules are depicted as yellow, green, and cyan, respectively.
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found to be located near the entrance of the drug-binding
pocket, it seems that glycosylation at this position has no
impact on the binding of drugs by hAGP.
Interactions between hAGP andDrugs—For the first time, we
were able to obtain co-crystal structures of hAGP bound to
drug molecules. Our results provide new and detailed insights
into the structural basis of the different drug-binding specific-
ities of the two major variants of the protein.
DSP and AMT are well known as ligands that bind to A var-
iant hAGP with a high degree of selectivity. These two drugs,
which are structurally quite similar, were observed to bind in
essentially the same manner to the central cavity (lobe I) in
hAGP, making contact with many of the same amino acids lin-
ing the binding pocket (Fig. 5, b and c). In particular, both com-
plexes reveal conserved edge-face contacts between the two
aromatic rings on the drugs and the aromatic side chains of
Phe-112 andPhe-49. This suggests that Phe-112 andPhe-49 are
critical residues for the binding of these drugs to the A variant.
Notably, the residue at position 112 in the F1*S variant is leu-
cine; therefore, this difference may contribute to the reduced
binding affinity ofDSP andAMT for the F1*S variant. There are
additional differences that explain why DSP and AMT prefer-
entially bind to the A variant.Whereas Ser-114 in the A variant
is involved in a water-mediated hydrogen bond with the amide
group of DSP, this residue is replaced by Phe-114 in the F1*S
variant. Thus, not onlywould the hydrogen bond toDSPbe lost,
but the larger side chain in F1*S would be expected to impede
the binding of DSP (and AMT) due to steric hindrance in the
binding pocket (Fig. 5a). Therefore, the differences in the
amino acid residues between the twomajor hAGP variants at
positions 112 and 114 appear to be crucial for the high selec-
tivity of the A variant for DSP, AMT, and other A variant-
specific drugs that contain two aromatic rings with similar
configurations.
CPZ was also observed to bind to the central cavity (lobe I).
CPZ binds to the F1*S and A variants with equal affinity (11).
Although some structural similarities exist between CPZ and
DSP and AMT, its aromatic ring system is more planar and has
a chlorine atomattached to one end. Collectively, these features
appear to result in a reorientation of the ring system in the CPZ
complex compared with the conformations of bound DSP and
AMT. In particular, CPZ is involved in parallel stacking inter-
actions with the Phe-112 side chain of the A variant. Modeling
studies suggest that CPZmay bind with the same orientation in
the pocket of the F1*S variant, despite the replacement of Phe-
112 by Leu in this variant. Moreover, maintenance of the same
orientation would not result in any steric hindrance due to the
substitution of Ser-114 by Phe in the F1*S variant, in contrast to
our predictions for DSP and AMT (Fig. 5b). This provides a
plausible explanation for the nonselectivity of hAGP variants
for CPZ.
Skerra and co-workers (18) modeled the mode of binding of
nonspecific diazepam and progesterone to the crystal structure
of F1*S hAGP and found that, among the amino acid residues
predicted to contact diazepam, Val-92, Leu-112, and Phe-114
are different from the residues for the A variant. As discussed
above, our structures suggest that the residues at positions 112
and 114 are critical for the selectivity of the hAGP variant.
Glu-92 in the A variant of hAGP, which is located near the top
of the drug-binding cavity, is replaced byVal in the F1*S variant.
We recently found that this residue is an important determi-
nant for the binding of propafenone, a representativeA variant-
specific drug (35). The mutation of Glu-92 to Val in the A var-
iant reduced propafenone binding, whereas introduction of the
converse V92E mutation into the F1*S variant increased the
binding capacity of this drug. These results suggest that
the negatively charged side chain onGlu-92may be required for
the binding of propafenone to hAGP. In this study, Glu-92 is
located near Arg-90 (supplemental Fig. S2), which interacts
FIGURE 3. Comparison of the amino acid residues and the structure
between the hAGP variant. Shown are the overall structure of the A variant
represented in schematic form (a) and the top view into the -barrel with
surface representation (b). A superposed view of the F1*S and A variants is
presented (c). The dashed oval represents the difference in the position of
-helix 2 between the hAGP variants. Local structural differences in the GH
loop (d) and near the binding pocket (e) between hAGP variants in the region
indicated by the dashed oval in c are shown. Amino acid residues in the F1*S
variant (Protein Data Bank code 3BX6) are colored hot pink (a and b), and the
F1*S and A variants are colored gray and pink (c and d).
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with DSP or AMT. Therefore, Glu-92 in the A variant may be
indirectly involved in the binding of propafenone. Alterna-
tively, Glu-92might contribute directly to binding by forming a
hydrogen bond with the amide group in the alkyl tail structure
of propafenone.
Skerra and co-workers (18) found that the binding pocket of
the F1*S variant is wide and consists of three lobes (I–III). Our
study indicates that the A variant maintains lobes I and II, but
not lobe III. This result shows that the binding region of the A
variant of hAGP is narrower than that of the F1*S variant, a
difference that may be a factor in its distinctive ligand selectiv-
ity. In fact, the selectively of ligand binding to the A variant
displays some common structural features, but this is not seen
for the case of the F1*S variant, which can recognizes ligands
with diverse structures such as warfarin, prazosin, dipyrida-
mole, and imatinib, etc. (11). To further explore this possibility,
additional crystallographic and ligand binding studies of F1*S
variant-ligand complexes will be needed in future studies.
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Figure. S1. Binding mode of the PEG molecule to the A variant. The PEG 
molecule is depicted as yellow sticks and balls. Amino acid residues involved 
in van der Waals interactions with the PEG molecule are depicted as sticks and 
balls. 
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Figure. S2. The Glu92 residue in the A variant. Glu92 is located near Arg90 
which interacts with (a) DSP or (b) AMT. 	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